lgd-2226 and Osteoporosis--Postmenopausal

lgd-2226 has been researched along with Osteoporosis--Postmenopausal* in 1 studies

Other Studies

1 other study(ies) available for lgd-2226 and Osteoporosis--Postmenopausal

Article	Year
Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators. Journal of medicinal chemistry, 2007, Oct-18, Volume: 50, Issue:21 The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis. Topics: Administration, Oral; Anabolic Agents; Androgen Receptor Antagonists; Androgens; Animals; Biological Availability; Bone Density Conservation Agents; Female; Humans; Hypogonadism; Male; Muscle, Skeletal; Organ Size; Osteoporosis, Postmenopausal; Prostate; Pyrrolidines; Quinolines; Quinolones; Rats; Stereoisomerism; Structure-Activity Relationship	2007

Article

Year

Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators.

Journal of medicinal chemistry, 2007, Oct-18, Volume: 50, Issue:21

The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis.

Topics: Administration, Oral; Anabolic Agents; Androgen Receptor Antagonists; Androgens; Animals; Biological Availability; Bone Density Conservation Agents; Female; Humans; Hypogonadism; Male; Muscle, Skeletal; Organ Size; Osteoporosis, Postmenopausal; Prostate; Pyrrolidines; Quinolines; Quinolones; Rats; Stereoisomerism; Structure-Activity Relationship

2007